Navigation Links
Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
Date:12/7/2008

TOKYO and EDISON, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.

The Phase III global study, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE-AF TIMI 48), will compare DU-176b with warfarin in preventing stroke and systemic embolic events (SEE) in patients with atrial fibrillation. The primary safety assessment will be the incidence of bleeding.

Results from a recently presented Phase II safety study showed that the incidence of major and clinically relevant non-major bleeding events reported in the once-daily DU-176b treatment groups (30 mg or 60 mg) was similar to that in the warfarin-treated patient group. The incidence of major and clinically relevant non-major bleeding events was significantly higher in the twice-daily DU-176b treatment groups (30 mg or 60 mg), compared to the warfarin group. The Phase III study will therefore randomize approximately 16,500 patients to one of three treatment groups: 30 mg DU-176b once daily, 60 mg DU-176b once daily, or warfarin. Those randomized to warfarin will be dosed once daily with dose adjustments to maintain International Normalized Ratio (INR) between 2.0 and 3.0.

This is an event-driven, Phase III, multinational, randomized, double-blind study with sites in North and South America, Africa, Asia, Europe, Australia and New Zealand. The expected median treatment duration of the study is 24 months; Daiichi Sankyo expects the study to conclude in the first half of 2012.

"There is a need for a safe and effective option for the prevention of clotting or stroke in patients with atrial fibrillation other than the current standard of care, warfarin, which
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
3. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
8. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
9. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
10. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
11. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Auxilium Pharmaceuticals, ... specialty biopharmaceutical company, today announced that the Company ... from its partner Asahi Kasei Pharma Corporation (Asahi ... successful submission of a regulatory application to the ... XIAFLEX ® (collagenase clostridium histolyticum) for the ...
(Date:7/31/2014)... 31 juli 2014 De Pfizer Clinical Research ... voor gezonde vrijwilligers van Japanse komaf voor medewerking aan ... gevestigde PCRU is één van twee onderzoekseenheden van ... levens te verbeteren door de ontdekking en ontwikkeling van ... op zoek naar mannen en vrouwen van Japanse komaf ...
(Date:7/30/2014)... Inc. (NASDAQ: HOLX ) today announced its ... 2014. Third Quarter Financial Highlights and Recent ... reflecting operational growth of 0.5% and a positive currency ... the prior year. , Revenues grew in three ... grew 3.5%. , GYN Surgical revenues grew 3.5%. ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 5Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17
(Date:7/31/2014)... 31, 2014 The shale gas development ... top of current U.S. natural gas production has raised ... and bust” cycle, similar to previous resource extraction experiences ... today by Washington & Jefferson College’s (W&J) Center for ... Institute (ELI) confirms that the gas boom in Pennsylvania ...
(Date:7/31/2014)... Computer Resources of America, Inc. (CRA), ... York City, has been awarded the contract to rewire ... of a large global bank. The bank is a ... Ramnarayan, Chief Executive Officer of CRA said, “Being awarded ... us to further develop what has already been a ...
(Date:7/31/2014)... The Brosix team takes great pride in giving back ... part in the TuxCon conference at International Fair Plovdiv. ... events, including speakers from Bulgaria, Turkey and Greece. Topics ... software for mobile, embedded and wearable devices. , Brosix ... conference, presenting a segment entitled “Mobile Applications that Communicate.” ...
(Date:7/31/2014)... July 31, 2014 Perhaps some people are ... are getting old from the first day when we were ... ups and downs during their whole life. Some people may ... (like China), it is not necessary for people to worry ... help; FODAY Auto, a famous China automobile manufacturer , ...
(Date:7/31/2014)... 31, 2014 Updox, the industry ... announces the release of a “Twelve Questions to Ask When ... that are evaluating Health Information Service Providers (HISPs) for Direct ... utilize MEDITECH and Epic electronic health records (EHRs) need to ... of care using the Direct protocol. , “Selecting ...
Breaking Medicine News(10 mins):Health News:Pennsylvania’s Shale Gas: Examining the Boom and Bust Cycle 2Health News:Pennsylvania’s Shale Gas: Examining the Boom and Bust Cycle 3Health News:Global Bank Awards CRA with Network Infrastructure Contract 2Health News:Brosix Takes Part in TuxCon Conference 2Health News:FodayAuto.com: Do Not Be Afraid of Getting Old 2Health News:Updox Introduces Resources to Help Hospitals Choose the Right HISP for Direct Messaging 2Health News:Updox Introduces Resources to Help Hospitals Choose the Right HISP for Direct Messaging 3Health News:Updox Introduces Resources to Help Hospitals Choose the Right HISP for Direct Messaging 4
... Pharmacy Join Forces for Jude Andrew ... Adams Charitable Fund, ... announce that they have joined to offer Braun Pharmacy,customers free overnight ... filled for individual cycles to the,Jude Andrew Adams Charitable Fund, a ...
... Flagship Global Health,Inc. (OTC Bulletin Board: FGHH) today ... 2008 as the date for the Company,s annual stockholder,s,meeting. ... later date., About Flagship Global Health, Flagship ... level of healthcare quality for its members, whether,they are ...
... One of the nations oldest and most respected ... travel fellowships to underrepresented minority students and scientists to ... April 5-9. The American Physiological Society (APS), which administers ... the travel awards. , APS administers the program with ...
... MINNEAPOLIS, March 18 A landmark study ... Association documents how medication,therapy management (MTM) services, ... Care System(TM), produced both improved,clinical outcomes and ... Economic Outcomes of Medication Therapy Management Services:,The ...
... In an,unprecedented election, nursing home and home ... of United Healthcare,Workers-West, demonstrating their unwillingness to ... Union local branch., (Photo: http://www.newscom.com/cgi-bin/prnh/20080318/DC17028 ... disinformation campaign,aimed at suppressing voter turnout, 99 ...
... Smart Balance Inc.,(Nasdaq: SMBL ) announced today ... annual Citi Small/Midcap Conference in Las Vegas, NV, at,12:25 ... Hughes, Chairman and Chief Executive Officer and Alan Gever,Executive ... at the conference as well as through the webcast. ...
Cached Medicine News:Health News:Infertility Consultancy and Chicago Pharmacy Bring Hope to Infertile Couples 2Health News:52 minority scientists receive travel fellowships to Experimental Biology 2008 2Health News:52 minority scientists receive travel fellowships to Experimental Biology 2008 3Health News:MTM Study Reports Improved Quality and Economic Outcomes Using Medication Management Systems' Assurance Pharmaceutical Care System(TM) 2Health News:California Nursing Home, Homecare Workers Vote Overwhelmingly to Preempt Forced Transfer 2Health News:California Nursing Home, Homecare Workers Vote Overwhelmingly to Preempt Forced Transfer 3Health News:Smart Balance to Webcast Presentation at Citi Small/Midcap Conference 2
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
... This remarkable anti-reflux valve is ... housing which prevents the valve ... when in sitting or reclining ... self-cleaning and interference free ensuring ...
... AggRAM, for platelet aggregation and ristocetin ... with the power of Windows-based software ... to two AggRAM modules can be ... computer so you can configure your ...
The Multiple Perfusion set provides simultaneous perfusion of the aortic root and up to three or more vein grafts. The set features an inlet port with female luer and clamp attached to an adapter whi...
Medicine Products: